SVNT stock performance?

Savient Pharmaceuticals Inc (SVNT) news stock charts

Savient Pharmaceuticals Inc (SVNT) Investment Summary:

We are a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader markets. We are currently developing Puricase®, which we refer to as pegloticase, which is being developed for the control of uric acid in patients with gout whose signs and symptoms are inadequately controlled by conventional urate lowering therapy due to ineffectiveness, dose limiting toxicity, hypersensitivity or other contraindications. In 2001, pegloticase received “orphan drug” designation by the U.S. Food and Drug Administration, or FDA, which may allow it to receive orphan drug exclusivity if and when pegloticase is approved. Orphan drug exclusivity may prevent competitive versions of the same drug for the same indication from entering the market for a period of seven years from the time of FDA approval of pegloticase.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000950123-08-002988.html#FIS_BUSINESS"   
www.savientpharma.com
Founded in 1980

SAVIENT PHARMACEUTICALS INC (SVNT:NASDAQ)

LAST $14.41 USD
CHANGE TODAY -0.16 -1.10%
VOLUME 23.4K
As of 9:37 AM 03/22/10 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of SAVIENT PHARMACEUTICALS INC (SVNT)

OPEN
$14.49
PREVIOUS CLOSE
$14.57
DAY HIGH
$14.59
DAY LOW
$14.41
52 WEEK HIGH
09/16/09 - $16.62
52 WEEK LOW
04/8/09 - $4.38
MARKET CAP
964.8M
AVERAGE VOLUME 10 D
806.5K
EPS TTM
$-1.34
SHARES OUTSTANDING
67.0M
SVNT Does Not Pay Dividends
P/E TTM
--
K = Thousands  M = Millions  B = Billions

related news

Late Sell-Off Slams U.S. Stocks

Deepening concerns about a recession prompted an accelerated downturn in equities in the final hour of trading Monday

Key developments for SAVIENT PHARMACEUTICALS INC (SVNT)

Savient Resubmits Biologics License Application for Krystexxa (Pegloticase) for Treatment of Chronic Gout in Patients Refractory to Conventional Therapy

Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXAT (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. The resubmission includes data from three consecutive manufacturing validation batches of the pegloticase active pharmaceutical ingredient (API) drug substance, additional and improved analytical methods for the control and release of pegloticase API and KRYSTEXXA and other data which are designed to address the issues cited by the FDA in its July 31 2009 Complete Response Letter (CRL). It also includes a Safety Update from the remaining studies that were ongoing at the time of the previous 120-Day Safety Update. Additional documents included in the resubmission are proposals for product labeling and prescribing information, REMS program materials and a patient Medication Guide, all of which were requested in the CRL and the Company believes are consistent with previous discussions with the FDA associated with the Company's September 14, 2009 Type A meeting.

Savient Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009

Savient Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. The net loss for the fourth quarter of 2009 was $0.2 million, or $0.00 per basic and diluted share, on total revenues of $0.9 million, compared with a net loss of $24.2 million, or $0.45 per basic and diluted share, on total revenues of $1.1 million for the fourth quarter of 2008. Significantly offsetting the net loss for the three months ended December 31, 2009 is a non-cash gain of $12.4 million due to a valuation adjustment relating to warrants that issued in connection with the April 2009 registered direct offering. On a non-Generally Accepted Accounting Principles (GAAP) basis, excluding the $12.4 million valuation adjustment, the net loss for the fourth quarter of 2009 was $12.6 million, or $0.19 per basic and diluted share, compared with a GAAP net loss for the fourth quarter of 2008 of $24.2 million, or $0.45 per basic and diluted share. The decrease in revenue was due to lower net product sales of the authorized generic oxandrolone product due to increased generic competition. Non-GAAP net Loss was $12.6 million or $0.19 per basic and diluted share as compared to $24.2 million $0.45 per basic and diluted share for the same period prior year. The net loss for the year ended December 31, 2009 was $90.9 million, or $1.51 per basic and diluted share, on total revenues of $3.0 million, compared with a net loss of $84.2 million, or $1.57 per basic and diluted share, on total revenues of $3.2 million for the same period in 2008. The net loss for the year ended December 31, 2009 includes a non-cash charge of $11.7 million due to a valuation adjustment relating to warrants that issued in connection with April 2009 registered direct offering. On a non-GAAP basis, excluding the $11.7 million non-cash charge, the net loss for the year ended December 31, 2009 was $79.2 million, or $1.32 per basic and diluted share, compared with a GAAP net loss of $84.2 million for the year ended December 31, 2008, or $1.57 per basic and diluted share. The decrease in revenue resulted primarily from lower net product sales of OxandrinR and the authorized generic oxandrolone product due to increased generic competition. Non-GAAP net Loss was $79.2 million $1.32 per basic and diluted share as compared to $84.2 million $1.57 per basic and diluted share for the same period prior year.

Savient Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on February 26, 2010).

Savient Pharmaceuticals, Inc. expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on February 26, 2010).

Savient Pharmaceuticals Inc financial resources

otc, otcbb, pinksheet, SVNT, ob Savient Pharmaceuticals Inc

SVNT Competitors

Company Last Change
Hi-Tech Pharmacal Co Inc $21.68 USD -0.49
Lannett Co Inc $5.01 USD 0.00
OraSure Technologies Inc $5.35 USD -0.05
Quigley Corp/The $2.03 USD 0.00
Viropharma Inc $13.98 USD +0.52
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation SVNT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 321.7x
Price/Book 15.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 293.0x

SVNT

 | 

SVNT transactions

Type
Date
Target
No transactions in the last 6 months.

More Recent Financial News About Savient Pharmaceuticals Inc

Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy

Quote: ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tabl...
Read article

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a

Quote: SAVIENT PHARMACEUTICALS INCRequest a Trial to NEW EDGAR Online Pro Form 8-K for SAVIENT PHARMACEUTICALS INC 3-Mar-2010Results of Operations and Financial Condition, Financial Statements a Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent provide...
Read article

Savient posts smaller loss due to warrant gain

Quote: (AP) -- Drugmaker Savient Pharmaceuticals Inc. is reporting a smaller fourth-quarter loss due to a one-time gain.Savient said it lost $219,000 in the fourth quarter. On a per-share basis the company broke even. That included a $12.4 million value adjustment on stock warrants it issued during a stock sale earlier in 2009. Leaving out that benefit, the company said it lost 19 cents per share.Thomson Reuters says analysts expected a loss of 29 cents per share.In the fourth quarter of 2008, Savient ...
Read article

Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results

Quote:
Read article

Savient to Present at the Cowen and Company 30th Annual Health Care Conference

Quote: ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tabl...
Read article

Savient posts smaller loss due to warrant gain

Quote: (AP) -- Drugmaker Savient Pharmaceuticals Inc. is reporting a smaller fourth-quarter loss due to a one-time gain.Savient said it lost $219,000 in the fourth quarter. On a per-share basis the company broke even. That included a $12.4 million value adjustment on stock warrants it issued during a stock sale earlier in 2009. Leaving out that benefit, the company said it lost 19 cents per share.Thomson Reuters says analysts expected a loss of 29 cents per share.In the fourth quarter of 2008, Savient ...
Read article

Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results

Quote:
Read article

Savient to Present at the Cowen and Company 30th Annual Health Care Conference

Quote: ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tabl...
Read article

Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010

Quote: 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010. Paul Hamelin, President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on February 26, 2010 to discuss these results and to answer questions.www.sav...
Read article

Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010

Quote: 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010. Paul Hamelin, President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on February 26, 2010 to discuss these results and to answer questions.www.sav...
Read article

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: Other Events. On October 8, 2009, Savient Pharmaceuticals, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities Inc., as representative of the several underwriters listed in Schedule 1 of the Underwriting Agreement (the "Underwriters"), relating to the underwritten offering of 4,300,000 shares (the "Shares") of the Company's common stock, $0.01 par value per share (the "Offering")...
Read article

Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

Quote: SVNTNews) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009. The presentation is scheduled to begin on Tuesday, November 3, 2009 at 1:35 p.m. Eastern Time. The conference will be held at The Waldorf Astoria in New York, NY, November 3-4, 2009. http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days. ABOUT SAVIENT PHARMACEUT...
Read article

Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results

Quote:
Read article

Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities

Quote: 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXAâ„¢ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010. The Company announced that:The Company conducted the...
Read article

Savient To Present at the 28th Annual JP Morgan Healthcare Conference

Quote: Francis Hotel in San Francisco, CA.www.savient.com.Following the live presentation, a replay of the webcast will be made available on the Company's web site for 30 days.ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, fo...
Read article

Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities

Quote: 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXAâ„¢ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010. The Company announced that:The Company conducted the...
Read article

Savient To Present at the 28th Annual JP Morgan Healthcare Conference

Quote: Francis Hotel in San Francisco, CA.www.savient.com.Following the live presentation, a replay of the webcast will be made available on the Company's web site for 30 days.ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, fo...
Read article

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: Other Events On October 15, 2009, Savient Pharmaceuticals, Inc. (the "Company") announced the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, the Company sold a total of 4,945,000 shares of its common stock at a price to the public of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, the...
Read article

Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009

Quote: Eastern Time on November 19, 2009 by dialing (888) 203-1112 (domestic) or (719) 457-0820 (international) and entering conference ID number 6621643.About Savient Pharmaceuticals, Inc.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as P...
Read article

Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

Quote: SVNTNews) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009. The presentation is scheduled to begin on Tuesday, November 3, 2009 at 1:35 p.m. Eastern Time. The conference will be held at The Waldorf Astoria in New York, NY, November 3-4, 2009. http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days. ABOUT SAVIENT PHARMACEUT...
Read article

Would you like to leave a comment about Savient Pharmaceuticals Inc SVNT

Besides Savient Pharmaceuticals Inc's Stock there is more great penny stock and market information at Realpennies